Market Introduction
Cell therapy bioprocessing is a subfield of bioprocess engineering that bridges cell therapy and bioprocessing (i.e., biopharmaceutical manufacturing). Cell therapy is one of the fastest-growing areas of the life sciences. It entails delivering entire living cells to a patient to treat disease.
Thus, the growing approvals for cell therapies is expected to create a significant demand for cell therapy bioprocessing in the coming years, which is further anticipated to drive the cell therapy bioprocessing market.
The global distribution of COVID-19 interfered with established clinical trials for a variety of reasons, as summarized in a recent Nature News article. Simultaneously, the pandemic has enabled massive private and public mobilization to promote new diagnostics, prophylactic vaccinations, and treatments. Cell and gene therapy manufacturers were involved in every aspect of this mobilization. According to clinicaltrials.gov, approximately 70 ongoing studies of cell and gene therapies to prevent or treat COVID-19 began on May 12, 2020. Products for cell therapy with anti-inflammatory pathways that appear to be well suited to COVID-19 therapy are also being investigated. Cell and gene therapy production may necessitate the use of a variety of human and animal biological materials. The risk that products derived from human plasma and blood will contaminate must be explained, but voluntary screening and testing of donors and donor materials used for SARS-CoV-2 can be a prudent measure. Manufacturing phase (open vs. closed): For early studies, those products are still produced in less closely or openly closed platforms, using an environmental protection biologic safeguard cabinet that is frequently located in a non-cGMP setting, despite an ongoing trend toward moving from the use of open production platforms to closed systems. This lower control level increases the risk of SARS-CoV-2 operators contaminating products. All such aspects will add to the future demand for the North America region's cell therapy bioprocessing market.
Market Overview and Dynamics
The Cell therapy bioprocessing market in North America is expected to grow from US$ 5,591.9 million in 2021 to US$ 13,701.0 million by 2028; it is estimated to grow at a CAGR of 13.7% from 2021 to 2028. Automated procedures will also help in scaling-up the production volumes and continuous production of different batches with minimal tracking. It will also increase productivity by enabling the rapid expansion of manufacturing capability. There have been several instances of companies developing automated processes. In July 2020, Thermo Fisher Scientific Inc., and Lyell Immunopharma entered a partnership to develop and manufacture processes to design effective cell therapies for cancer patients. Under this partnership, the companies aim to improve fitness of T-cells and support the development of an integrated cGMP compliant platform (system and software) along with reagents, consumables, and instruments. Likewise, in March 2019, Lonza entered a partnership with Israel’s Sheba Medical Center to provide automated and closed CAR-T manufacturing using its point-of-care Cocoon cell therapy manufacturing platform. Thus, the adoption of automated procedures will help overcome the challenges associated with cell therapy bioprocessing and offer growth opportunities to the market players that will contribute to the market growth in the coming years.
Key Market Segments
In terms of technology, the bioreactors segment accounted for the largest share of the North America cell therapy bioprocessing market in 2020. In terms of cell type, the stem cell segment accounted for the largest share of the North America cell therapy bioprocessing market in 2020. In terms of indication, the oncology segment accounted for the largest share of the North America cell therapy bioprocessing market in 2020. In terms of end user, the academic and research institute segment held a larger market share of the cell therapy bioprocessing market in 2020.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the Cell therapy bioprocessing market in North America are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Fresenius Kabi Ag., Asahi Kasei Corporation, Sartorius Ag, Merck Kgaa, Thermo Fisher Scientific Inc., Corning Incorporated, Cytiva (Ge Healthcare), Lonza, Repligen, and Catalent Inc.
Reasons to buy report
- To understand the North America Cell therapy bioprocessing market landscape and identify market segments that are most likely to guarantee a strong return
- Stay ahead of the race by comprehending the ever-changing competitive landscape for North America Cell therapy bioprocessing market
- Efficiently plan M&A and partnership deals in North America Cell therapy bioprocessing market by identifying market segments with the most promising probable sales
- Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form North America Cell therapy bioprocessing market
- Obtain market revenue forecast for market by various segments from 2021-2028 in North America region.
NORTH AMERICA CELL THERAPY BIOPROCESSING MARKET SEGMENTATION
By Technology
- Bioreactor
- Lyophilization
- Electrospinning
- Control flow Centrifugation
- Ultrasonic Lysis
- Genome Editing Technology
- Cell Immortalization Technology
- Viral Vector Technology
By Cell Type
- Stem Cell
- Immune Cell
- Human Embryonic Stem Cell
- Pluripotent Stem Cell
- Hematopoetic Stem Cell
By Indication
- Cardiovascular Disease (CVD)
- Oncology
- Wound Healing
- Orthopedic
- Others
By End User
- Hospitals and Clinics
- Diagnostic Centers
- Regenerative Medicine Centers
- Academic and Research Institute
By Country
-
North America
- US
- Canada
- Mexico
Companies Mentioned
- Fresenius Kabi Ag.
- Asahi Kasei Corporation
- Sartorius Ag
- Merck Kgaa
- Thermo Fisher Scientific Inc.
- Corning Incorporated
- Cytiva (Ge Healthcare)
- Lonza
- Repligen
- Catalent Inc
North America Cell Therapy Bioprocessing Market Strategic Insights
North America Cell Therapy BioprocessingMarket Report Highlights
| Report Attribute | Details |
| Market size in 2021 | US$ 5,591.9 Million |
| Market Size by 2028 | US$ 13,701.0 Million |
| CAGR (2021 - 2028) | 13.7% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Technology
|
|
Regions and Countries Covered
|
|
| North America | US, Canada, Mexico |
| Market leaders and key company profiles |
|
North America Cell Therapy Bioprocessing Market Country and Regional Insights
